In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.
about
"Stormy waters ahead": global emergence of carbapenemasesThree decades of beta-lactamase inhibitorsThe β-Lactams Strike Back: Ceftazidime-AvibactamStrategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infectionsNXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosisTargeting Antibiotic ResistanceClinical management of infections caused by multidrug-resistant EnterobacteriaceaePopulation Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307.Newer antibacterial drugs for a new century.In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.Postgenomic strategies in antibacterial drug discovery.New trends in aminoglycosides use.Reclaiming the efficacy of β-lactam-β-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime.Antibiotic discovery in the twenty-first century: current trends and future perspectives.In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.Investigational antimicrobial agents of 2013.Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility.Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniaePlazomicin: an investigational therapy for the treatment of urinary tract infections.Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsIn Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system.Understanding and overcoming aminoglycoside resistance caused by N-6'-acetyltransferase.In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China.Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104.Status report on carbapenemases: challenges and prospects.Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.Development of new drugs for an old target: the penicillin binding proteins.Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens.β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.
P2860
Q21131125-0B121FC6-625D-4C24-B30A-FF1574E2640FQ24646623-8E14C052-B051-45A0-845F-586342A60A8BQ26796425-1316F69C-29C5-499D-8E9E-DC33829939D9Q26859978-3576DD37-D6E2-4E46-A1E9-747673945BE0Q27679097-3ACF82AE-CED4-4EC8-952B-FF5A2A225F51Q28078130-84753A2E-1720-44AB-918E-ED3BE99F364CQ28246841-19230695-0735-4FA8-BD59-BEBC4FAD5235Q30402058-088DF0AA-E936-475F-A5E4-9E47B376A8A8Q30433333-FA00F6CF-C03D-4D2D-83BB-9216FBF530AAQ33558996-713D9191-607B-4BB4-B655-CBE131F06822Q33622976-C4920081-3E95-4D37-B63F-6383CD1F96F6Q33745572-194A43D0-0F0F-48EB-A74C-FC233251A2A5Q33951177-5642D02D-EEAA-4058-B8B4-294F54CF10C9Q34058217-789AC52A-D1BE-4861-B69C-02B178AF4E5CQ34121033-1567B414-B567-412E-BBD1-877C11A9177EQ34134689-FC28A0E1-AF24-47FA-8A38-FAE3695D637DQ34325573-AB867092-8E01-446B-BE6A-B310BE190B0CQ34375204-9D320F06-73A5-4389-9083-FFE6FF7C8FBAQ34402134-C68E4741-B79B-47C0-A95D-0FCD8A5F9ED4Q34433108-505668A9-883E-4323-8DCF-C3E21EBC3AE7Q34483491-D60C2273-9988-4971-8F60-BC69876DC879Q34673393-7DE57F70-0C4A-4085-972C-AC18722F0B88Q35005107-3DAFA5C0-E51C-4FEB-91ED-2CFF735B4D68Q35065798-36A7B1ED-C517-40CF-A71D-A15FE165DA11Q35168955-6827E96D-96F7-4D34-86C9-64560824BA1BQ35764780-634D5FAF-02B0-43EB-B9E9-BE7FBC0E5918Q36361921-7814BCCD-709C-4C24-A992-E3DFC12B7E53Q36888062-7B00DD4A-2D2D-48C2-8EA1-8CE41DC204EDQ37120182-124C525D-B485-4DBB-95FE-FC34E77C6939Q37146405-7C337F6C-93C2-4DE8-AFBE-8AF637D36C13Q37383945-4C6AA528-4117-42A4-AB32-3640FA221E9AQ37528001-A09F4D55-F9E5-4F17-A9BD-62CB6DF7EC18Q37643595-B5DA5B07-63B9-4356-9889-38AD9EC065B8Q37845845-F4DF60D6-602C-40B9-AEC6-B3564C014B16Q37879199-EFFD0DEE-7560-4A45-816D-FC8D5233C79AQ38001333-546B8B84-EFDE-4223-A33D-479D09D6F0A9Q38055325-D5773C41-6B85-4A76-B6FE-18EB7FFF814EQ38058355-32C58953-5912-4A36-B0EC-DE170E3C65E3Q38130715-67EE276F-2946-4BDB-AB53-7F99BF5EE79AQ38267323-3F91101F-75B2-4C0F-93B3-E37396C6CCB4
P2860
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@en
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@nl
type
label
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@en
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@nl
prefLabel
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@en
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@nl
P2860
P356
P1476
In vitro activity of NXL104 in ...... producing KPC carbapenemases.
@en
P2093
Andrea Endimiani
Yuvraj Choudhary
P2860
P304
P356
10.1128/AAC.00641-09
P407
P577
2009-06-15T00:00:00Z